ABCL (AbCellera Biologics Inc.) Stock Financials & Earnings | Market Cap Arena

ABCL (AbCellera Biologics Inc.) Stock Financials & Earnings | Market Cap Arena

ABCLAbCellera Biologics Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Revenue (TTM)$75M

Net Income (TTM)-$146M

EPS (TTM)-$0.49

Free Cash Flow (TTM)-$174M

Gross Margin100.0%

Op. Margin-289.0%

Net Margin-194.9%

FCF Margin-231.7%

P/S Ratio (TTM)14.6x

P/E Ratio (TTM)—

YoY Rev Growth+160.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$12M	$12M	-$65M
Q2 23	$10M	$10M	-$51M
Q3 23	$7M	$7M	-$55M
Q4 23	$9M	$9M	-$66M
Q1 24	$10M	$10M	-$55M
Q2 24	$7M	$7M	-$93M
Q3 24	$7M	$7M	-$94M
Q4 24	$5M	$5M	-$73M
Q1 25	$4M	$4M	-$63M
Q2 25	$17M	$17M	-$50M
Q3 25	$9M	$9M	-$76M
Q4 25	$45M	$45M	-$29M

Valuation

Quarter	P/S	P/E
Q1 23	6.1x	—
Q2 23	7.6x	—
Q3 23	21.8x	—
Q4 23	28.9x	—
Q1 24	30.7x	—
Q2 24	33.2x	—
Q3 24	33.3x	—
Q4 24	38.1x	—
Q1 25	47.5x	—
Q2 25	33.4x	—
Q3 25	31.1x	—
Q4 25	14.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$44M	-$59M
Q2 23	$20M	-$8M
Q3 23	-$106K	-$20M
Q4 23	-$20M	-$34M
Q1 24	-$42M	-$66M
Q2 24	-$29M	-$49M
Q3 24	-$29M	-$48M
Q4 24	-$8M	-$24M
Q1 25	-$12M	-$22M
Q2 25	-$32M	-$46M
Q3 25	-$53M	-$62M
Q4 25	-$35M	-$45M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$15M
Q2 23	$27M
Q3 23	$20M
Q4 23	$14M
Q1 24	$24M
Q2 24	$20M
Q3 24	$19M
Q4 24	$16M
Q1 25	$11M
Q2 25	$13M
Q3 25	$9M
Q4 25	$10M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-96.1%	-15.9%
Q2 23	-78.1%	+13.1%
Q3 23	-93.5%	-3.4%
Q4 23	-57.4%	+26.8%
Q1 24	-18.4%	-15.9%
Q2 24	-27.2%	+64.0%
Q3 24	-1.4%	+62.9%
Q4 24	-45.0%	+3.4%
Q1 25	-57.5%	+3.2%
Q2 25	+133.3%	-33.8%
Q3 25	+37.6%	-14.9%
Q4 25	+788.2%	-5.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$15M	126.9%
Q2 23	$0	0.0%
Q3 23	$16M	240.4%
Q4 23	$16M	179.2%
Q1 24	$17M	174.9%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$15M	301.5%
Q1 25	$15M	349.1%
Q2 25	$14M	83.2%
Q3 25	$14M	155.2%
Q4 25	$13M	28.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$53M	$15M	$4M	—
Q2 23	$36M	$16M	$4M	—
Q3 23	$38M	$14M	$3M	—
Q4 23	$49M	$16M	$3M	—
Q1 24	$39M	$17M	$3M	—
Q2 24	$41M	$20M	$3M	—
Q3 24	$41M	$19M	$3M	—
Q4 24	$46M	$16M	$3M	—
Q1 25	$42M	$16M	$3M	—
Q2 25	$39M	$19M	$3M	—
Q3 25	$55M	$22M	$3M	—
Q4 25	$50M	—	—	$17M

Revenue Segments

Quarter	License	Milestone Payments	Research Fees
Q1 23	$372K	$1M	$11M
Q2 23	$226K	—	$10M
Q3 23	$186K	—	$6M
Q4 23	$185K	$250K	$9M
Q1 24	$180K	—	$10M
Q2 24	$370K	$2M	$5M
Q3 24	$218K	—	$6M
Q1 25	$167K	—	$4M
Q2 25	$10M	—	$7M
Q3 25	$138K	—	$9M
Q4 25	$36M	—	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$193M	$603M	$796M
Q2 23	$180M	$616M	$796M
Q3 23	$172M	$613M	$786M
Q4 23	$133M	$627M	$761M
Q1 24	$124M	$574M	$698M
Q2 24	$148M	$522M	$670M
Q3 24	$127M	$516M	$643M
Q4 24	$156M	$469M	$626M
Q1 25	$159M	$446M	$605M
Q2 25	$92M	$461M	$553M
Q3 25	$83M	$413M	$496M
Q4 25	$155M	$405M	$560M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	288M	-4.5%
Q2 23	289M	+0.4%
Q3 23	289M	+0.2%
Q4 23	291M	+0.5%
Q1 24	293M	+0.6%
Q2 24	294M	+0.5%
Q3 24	295M	+0.2%
Q4 24	295M	-0.1%
Q1 25	298M	+1.1%
Q2 25	299M	+0.3%
Q3 25	299M	+0.1%
Q4 25	299M	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$1M	206
FY 21	$938K	400
FY 22	$981K	495
FY 23	$65K	586
FY 24	$48K	600
FY 25	$134K	562